Format

Send to

Choose Destination
Cancer Sci. 2018 May;109(5):1292-1299. doi: 10.1111/cas.13580.

Podoplanin: An emerging cancer biomarker and therapeutic target.

Author information

1
Department of Physiology and Biophysics, Stony Brook University, Stony Brook, NY, USA.
2
Institute of Cardiovascular Science, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham, UK.
3
Division of Pathology, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa, Chiba, Japan.
4
Laboratory of Cancer Biology, Department of Integrated Biosciences, Graduate School of Frontier Sciences, The University of Tokyo, Kashiwa, Chiba, Japan.
5
Graduate School of Biomedical Sciences and Department of Molecular Biology, Rowan University School of Osteopathic Medicine, Stratford, NJ, USA.
6
Division of Experimental Chemotherapy, The Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan.
7
Graduate Institute of Biomedical Sciences, College of Medicine, Chang Gung University, Taoyuan, Taiwan, China.
8
Second Department of Surgery (Chest Surgery), University of Occupational and Environmental health, Kitakyushu, Fukuoka, Japan.
9
Department of Dermatology, Kyoto Prefectural University of Medicine Graduate School of Medical Science, Kyoto, Japan.
10
Division of Cardiovascular Medicine, Department of Medical and Health Sciences, Linköping University, Linköping, Sweden.
11
Department of Neurosurgery, Nagoya University School of Medicine, Nagoya, Japan.

Abstract

Podoplanin (PDPN) is a transmembrane receptor glycoprotein that is upregulated on transformed cells, cancer associated fibroblasts and inflammatory macrophages that contribute to cancer progression. In particular, PDPN increases tumor cell clonal capacity, epithelial mesenchymal transition, migration, invasion, metastasis and inflammation. Antibodies, CAR-T cells, biologics and synthetic compounds that target PDPN can inhibit cancer progression and septic inflammation in preclinical models. This review describes recent advances in how PDPN may be used as a biomarker and therapeutic target for many types of cancer, including glioma, squamous cell carcinoma, mesothelioma and melanoma.

KEYWORDS:

c-type lectin-like receptor 2; cancer; chemotherapy; podoplanin

PMID:
29575529
PMCID:
PMC5980289
DOI:
10.1111/cas.13580
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center